
Roche Phase III study misses COVID-19 endpoint
In the Phase III REMDACTA trial, the Swiss pharma major combined its cytokine storm blocker tocolizumab with Gilead Science’s viral transcription...

BioVersys gets €20m EIB loan to develop novel antibiotics
The venture debt loan is financed under the Infectious Diseases Finance Facility set up as part of Horizon 2020, the European Union’s research and...

LSP leads €21m round into Neurent Medical
Galway-based medical device company Neurent Medical, which is focussed on chronic inflammatory diseases of the sinuses and nasal passages said it...

Two companies aim for 2nd-gen COVID vaccines
As scientific papers provide hints that mutants of SARS-CoV-2 that carry the N501Y and E484K mutations are able to reproduce more rapidly as the...

EU life science PPPs face less budget in Horizon Europe
The EU’s Public-Private Partnerships (PPPs), which have been under fire by the European Parliament and were renamed into ‘European Partnerships‘, are...

MaxiVAX and Minaris Regenerative Medicine ink contract
Under the contract, Minaris will be responsible for the GMP manufacturing, freezing and shipping of MVX-ONCO-2, a cell-based immunotherapy for the...

miRNAs unmask vulnerability in breast cancer stem cells
The study results, published in the Journal of Cell Biology, reveal that targeting these microRNAs sensitivies cancer stem cells to certain...